NASDAQ:QTRX - Quanterix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $21.03 -0.08 (-0.38 %) (As of 01/20/2019 10:39 AM ET)Previous Close$21.03Today's Range$20.58 - $21.4452-Week Range$13.00 - $24.81Volume130,869 shsAverage Volume79,741 shsMarket Capitalization$466.82 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. Quanterix Corporation has collaboration agreements with DestiNA Genomics to focus on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122; and OncoGenesis Corp to develop a protein biomarker diagnostic test for cervical health using its Simoa Planar Technology. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts. Receive QTRX News and Ratings via Email Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QTRX Previous Symbol CUSIPN/A Webwww.quanterix.com Phone617-301-9400Debt Debt-to-Equity Ratio0.16 Current Ratio4.11 Quick Ratio3.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$22.87 million Price / Sales20.41 Cash FlowN/A Price / Cash FlowN/A Book Value$3.02 per share Price / Book6.96Profitability EPS (Most Recent Fiscal Year)($8.30) Net Income$-27,010,000.00 Net Margins-88.72% Return on Equity-52.35% Return on Assets-36.48%Miscellaneous Employees126 Outstanding Shares22,200,000Market Cap$466.82 million OptionableNot Optionable Quanterix (NASDAQ:QTRX) Frequently Asked Questions What is Quanterix's stock symbol? Quanterix trades on the NASDAQ under the ticker symbol "QTRX." How were Quanterix's earnings last quarter? Quanterix Corp (NASDAQ:QTRX) announced its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.07. The company earned $10.59 million during the quarter, compared to analysts' expectations of $9.57 million. Quanterix had a negative net margin of 88.72% and a negative return on equity of 52.35%. View Quanterix's Earnings History. When is Quanterix's next earnings date? Quanterix is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for Quanterix. What price target have analysts set for QTRX? 2 brokers have issued 1 year price targets for Quanterix's shares. Their forecasts range from $26.00 to $27.00. On average, they expect Quanterix's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price. View Analyst Price Targets for Quanterix. What is the consensus analysts' recommendation for Quanterix? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quanterix. What are Wall Street analysts saying about Quanterix stock? Here are some recent quotes from research analysts about Quanterix stock: 1. Canaccord Genuity analysts commented, "We think investors should own QTRX as it targets growth across 4 phases: 1) expansion in the life sciences research, followed by possible entry into new markets in 2) companion diagnostics; 3) point-of-care diagnostics; and 4) precision health and wellness screening, a $38 billion TAM. We reiterate our BUY rating and $27 PT. Q3 beat. Q3 revenues of $10.6M (+85% Y/Y, +61% adj.) topped our $8.4M (+47%)/ Street’s $8.3M, and included a 1-time payment of $1.3M from its licensing termination with BioMérieux. Product revs of $6.0M (+82% Y/Y) beat our $5.0M, while service revs (ex the 1-timer) of $3.0M was light of our $3.4M. QTRX beat us on consumables (+100% Y/Y beat our +70%) and instruments (+58% Y/Y beat our +30%). ~46% were in line with our 46.5%E. OPEX of $13.3M was above our $10.5ME. Net loss of ($7.7M) exceeded our ($6.9ME)." (11/7/2018) 2. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (10/10/2018) Has Quanterix been receiving favorable news coverage? News stories about QTRX stock have been trending extremely positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Quanterix earned a media sentiment score of 4.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. Who are some of Quanterix's key competitors? Some companies that are related to Quanterix include Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Scientific Industries (SCND), Pressure Biosciences (PBIO), Bio-Rad Laboratories (BIO.B) and PositiveID (PSID). Who are Quanterix's key executives? Quanterix's management team includes the folowing people: Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)Mr. Joseph S. Driscoll, Chief Financial Officer (Age 54)Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 60) When did Quanterix IPO? (QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers. How do I buy shares of Quanterix? Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Quanterix's stock price today? One share of QTRX stock can currently be purchased for approximately $21.03. How big of a company is Quanterix? Quanterix has a market capitalization of $466.82 million and generates $22.87 million in revenue each year. The company earns $-27,010,000.00 in net income (profit) each year or ($8.30) on an earnings per share basis. Quanterix employs 126 workers across the globe. What is Quanterix's official website? The official website for Quanterix is http://www.quanterix.com. How can I contact Quanterix? Quanterix's mailing address is 113 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-301-9400. MarketBeat Community Rating for Quanterix (NASDAQ QTRX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 138 (Vote Outperform)Underperform Votes: 154 (Vote Underperform)Total Votes: 292MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: How does a reverse stock split work?